Physician profile
Wendy E Weiss
NPI 1609867738
$16,804.65
in general payments reported to CMS, 2019-2025
46 companies · $2,344 in 2025
The $2,344 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,756 · 2020: $2,629 · 2021: $2,775 · 2022: $2,073 · 2023: $1,705 · 2024: $1,522 · 2025: $2,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,570.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,229.26 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,541.96 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,443.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,395.61 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $961.08 | 2019-2025 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $953.83 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Titan Pharmaceuticals, INC. | $920.92 | 2019 | |
| Pfizer INC. | $791.30 | 2019-2025 | |
| Allergan, INC. | $729.88 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $602.10 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $546.38 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $426.99 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $349.65 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $342.89 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $320.15 | 2022-2025 | Ingrezza |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $310.12 | 2019-2023 | Rexulti |
| Radius Health, INC. | $305.98 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $260.30 | 2019-2025 | Verquvo, Gardasil 9, Segluromet |
| Ardelyx, INC. | $253.21 | 2024-2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $231.20 | 2020-2024 | Austedo Xr, Ajovy |
| Ucb, INC. | $207.29 | 2021-2025 | Briviact, Nayzilam |
| Axsome Therapeutics, INC. | $206.45 | 2024-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $167.25 | 2022 | |
| Idorsia Pharmaceuticals US INC | $144.26 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $125.36 | 2024-2025 | |
| Therapeuticsmd, INC. | $123.51 | 2019-2021 | |
| Alkermes, INC. | $100.58 | 2020 | |
| Eisai INC. | $88.19 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $84.47 | 2020-2022 | |
| Mylan Specialty L.P. | $70.89 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.28 | 2020-2024 | Xifaxan |
| Genzyme Corporation | $60.00 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.39 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $56.84 | 2024-2025 | Cobenfy |
| Kowa Pharmaceuticals America, INC. | $42.21 | 2021-2022 | |
| Ibsa Pharma INC. | $40.49 | 2020 | |
| Exact Sciences Corporation | $36.91 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Indivior INC. | $31.52 | 2021 | |
| Seqirus USA INC | $28.37 | 2025 | Fluad, Flucelvax |
| Neurelis, INC. | $27.52 | 2023 | Valtoco |
| Apyx Medical Corporation | $23.34 | 2020 | |
| Merz North America, INC. | $23.29 | 2019 | |
| Corcept Therapeutics | $23.07 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $21.59 | 2021 | |
| Braeburn INC. | $16.99 | 2025 | Brixadi |
| Almatica Pharma LLC | $14.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.